Vaccine development at Valneva
"At Valneva, we take a specialized approach to vaccine development, focusing on disease targets that lack a preventative or therapeutic solution"Juan Caros Jaramillo MD, Chief Medical Officer
Our current clinical portfolio is composed of a number of highly differentiated vaccine candidates that are designed to provide preventative solutions to diseases with high unmet need.
VLA1553 is a single-shot vaccine candidate against chikungunya, a mosquito-borne disease that is highly prevalent in tropical and subtropical regions.
VLA15 is the only vaccine in advanced clinical development against Lyme disease, the most common tick-borne infection in the northern hemisphere.